Gastrointestinal Cancer | Specialty

Side Effect Management With Regorafenib in mCRC

November 8th 2014

Second- and Third-Line Therapies in mCRC

November 8th 2014

Goals of Therapy in Metastatic CRC

November 8th 2014

Selecting First-line Treatment in mCRC

November 8th 2014

Latest News & Insight: November 7, 2014

November 8th 2014

Dr. Venook Discusses the Approval of Ramucirumab Plus Paclitaxel

November 7th 2014

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the approval of ramucirumab plus paclitaxel for gastric cancer

FDA Approves Ramucirumab Plus Paclitaxel for Advanced Gastric Cancer

November 5th 2014

The FDA has approved the combination of ramucirumab and paclitaxel as a treatment for patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

Collaboration Accelerates KRAS Inhibitor Development

November 4th 2014

A novel first-in-class covalent KRAS inhibitor SML-8-73-1 has demonstrated promise in preclinical studies, prompting a 3-year research collaboration between the Dana-Farber Cancer Institute and Astellas Pharma Inc.

Colorectal Cancer: Right Test, Right Time

November 4th 2014

Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease, with molecular features defining emerging subtypes. Understanding which tests to order in which cases can better direct care for our patients. Increasingly, panel testing has advantages over individual genetic testing.

Financial Burden of Cancer Treatment Weighs Heavily on Patients

October 28th 2014

Nearly two-thirds of patients diagnosed with colorectal cancer report experiencing financial burden during their treatment, according to a study from the University of Michigan.

Fast Track Designation Granted to TAS-102 in mCRC

October 20th 2014

The FDA has granted a fast track designation to TAS-102 (tipiracil hydrochloride) as a treatment for patients with refractory metastatic colorectal cancer (mCRC), according to an announcement by Taiho Oncology, the company developing the drug in the United States.

Few Agents Better Than Somatostatin Analogs for Symptom Control in Carcinoid Syndrome

October 11th 2014

Somatostatin analogs remain the mainstay of medical therapy for symptom control in patients with carcinoid syndrome.

Axitinib Shows Promise in Carcinoid Tumors

October 10th 2014

The rate of PFS with axitinib in patients with advanced carcinoid tumors is promising.

Everolimus Improves Outcomes in Pancreatic Neuroendocrine Tumors

October 10th 2014

Treatment with the mTOR inhibitor everolimus improved overall survival by 6.34 months over placebo for patients with pancreatic neuroendocrine tumors.

Combination Therapies, Novel Targeted Agents Are Focus of Pancreatic NET Studies

October 10th 2014

Selection of first-line treatments and the rational sequencing of therapies are among the unresolved questions in the treatment of pancreatic neuroendocrine tumors.

Dr. Yao on Takeaways From the RADIANT-3 Trial

October 10th 2014

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses key takeaways from the RADIANT-3 trial for a community oncologist.

Dr. Kunz on Sequencing Agents for Pancreatic NETs

October 10th 2014

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses sequencing agents for the treatment of pancreatic NETs.

Dr. Saab on a Phase II Study of the Oncolytic Virus Reolysin for Pancreatic Cancer

September 30th 2014

Tanios Bekaii-Saab, MD, discusses the results of a phase II study of the oncolytic virus reolysin in the first-line treatment metastatic adenocarcinoma of the pancreas.

Expanded 80405 Study Mutation Analysis Fails to Resolve Targeted Therapy Quandary in mCRC

September 30th 2014

All patients with metastatic colorectal cancer should undergo RAS mutation testing to ensure optimal patient selection for EGFR inhibitor therapy.

Pembrolizumab Shows Promise in Advanced Gastric Cancer

September 29th 2014

In patients with advanced gastric cancer expressing PD-L1, pembrolizumab (Keytruda) has robust antitumor activity and an acceptable safety profile